Given that Wnt/β-catenin signaling is evolutionarily conserved and is inactive in the normal tissues, except for stem cell niches [36], targeting this signaling by the 11C9-HSP90 antibody–antigen system might provide future perspectives for the stem cell therapy of HCC. This evidence concerns the gene HSP90AB1 and hepatocellular carcinoma.